<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168829</url>
  </required_header>
  <id_info>
    <org_study_id>327494</org_study_id>
    <nct_id>NCT02168829</nct_id>
  </id_info>
  <brief_title>Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial</brief_title>
  <acronym>OCEAN</acronym>
  <official_title>The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is comparing medical approaches for stroke prevention in people who have atrial
      fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or
      substantially reduce the arrhythmia. AF is normally associated with an increased risk of
      stroke which in many patients can be prevented with appropriate blood thinner therapy. This
      trial will compare a strategy of oral anticoagulant therapy after successful ablation to
      therapy with an aspirin per day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized trial to investigate whether a strategy of
      ongoing, long-term oral anticoagulation with rivaroxaban 15 mg daily is superior to a
      strategy of antiplatelet therapy, ASA 75-160 mg, alone in preventing cerebral embolic events
      in moderately high risk patients following successful catheter ablation for atrial
      fibrillation..

      At least one year post-successful catheter ablation for AF or left atrial flutter/tachycardia
      without evidence of any clinically apparent arrhythmia recurrence based on at least one 24
      hour Holter and ECG within 6 months after the last ablation procedure and at least one 24
      hour Holter and ECG between 6 and 12 months post-ablation or beyond. Patient must have no
      atrial fibrillation, atrial flutter or atrial tachycardia &gt; 30 seconds detected on a minimum
      48 hour Holter monitor within two months prior to enrollment.

      Patients will be randomized in a 1:1 fashion to ASA 75-160 mg daily or rivaroxaban 15 mg
      daily. Patients will be seen at 6 months, one year and every year thereafter for a minimum of
      3 years. Blood chemistry tests, ECG, holters and patient quality of life questionnaires will
      be done annually.

      Cerebral MRI scanning at baseline, at year one and at three years will be done for assessment
      of silent cerebral infarction. MRI imaging will be performed using a specific protocol.

      A pre-specified subset of patients will undergo insertion of a implantable loop recorder
      (ILR) capable of automated AF detection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of stroke, systemic embolism and covert embolic stroke as detected by cerebral MRI</measure>
    <time_frame>3 years</time_frame>
    <description>Composite of stroke, systemic embolism and covert embolic stroke as detected by cerebral MRI. A patient will be considered to have a covert stroke if one or more lesions &gt; 15 mm has been detected between the baseline, the one year and final (3 year) MRI on T2 weighted and/or FLAIR imaging protocols.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical, overt stroke</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinical, Overt stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of one or more covert MRI stroke(s) &gt;15 mm</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Incidence of one or more covert MRI stroke(s) &gt;15 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all major and minor bleeding</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Composite of all major and minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding only</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Major bleeding only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding only</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Minor bleeding only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Intracranial hemorrhage (clinical and covert on MRI alone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Transient ischemic attack defined as presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting &lt;24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of non-primary endpoint MRI changes from baseline to final scan</measure>
    <time_frame>3 years</time_frame>
    <description>Occurrence of non-primary endpoint MRI changes from baseline to final scan including: quantification of cerebral atrophy, quantification of cerebral white matter changes, number of all new MRI lesions &gt; 3mm, &gt;5 mm, &gt; 15 mm, and &gt; 20 mm, and number of lesions detected exclusively on DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing</measure>
    <time_frame>3 years</time_frame>
    <description>Neuropsychological testing - performed at baseline and repeated at 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>3 years</time_frame>
    <description>Cost utilization and cost effectiveness analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1572</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban 15 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid (ASA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>Acetylsalicylic acid (ASA)</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patient must be at least one year post-successful catheter ablation(s) for atrial
             fibrillation without evidence of any clinically apparent arrhythmia recurrence defined
             as all of the following: No AF/AT/AFL on at least 24 hour Holter and an ECG (or
             equivalent) from 2-6 months after the last ablation, AND no AF/AT/AFL on at least 24
             hour Holter and an ECG any time after 6 months after the last ablation AND no
             AF/AT/AFL on at least 24 hour Holter and ECG 2 months before enrolment in the study.
             The Holter/ECG within 2 months of enrolment may also serve as the Holter performed 6
             months or later after the last ablation - see section 2.3.1 for details.

          2. Patient must have a CHA2DS2-VASc risk score of 1 or more. Patients in whom female sex
             or vascular disease are their sole risk factor may not be enrolled.

          3. Patient must be &gt;18 years of age.

          4. Patient must have non-valvular AF.

        Exclusion Criteria

          1. Patient does not meet all of the above listed inclusion criteria.

          2. Patient is unable or unwilling to provide informed consent.

          3. Patient is included in another randomized clinical trial or a clinical trial requiring
             an insurance.

          4. Patient has been on an investigational drug within 30 days of enrolment.

          5. Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin,
             phenobarbital, or carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or
             protease inhibitors) within 4 days of enrolment.

          6. Patient has creatinine clearance &lt; 30 mL/min.

          7. Patient has bleeding contra-indication to oral anticoagulation (such as bleeding
             diathesis, hemorrhagic disorder, significant gastrointestinal bleeding within 6
             months, intracranial/intraocular/ atraumatic bleeding history, fibrinolysis within 48
             hours of enrollment).

          8. Patient has other contraindication to oral anticoagulation or treatment with
             antiplatelet agent (such as allergy).

          9. Patient has a contraindication to magnetic resonance imaging (MRI) or is unlikely to
             tolerate due to severe claustrophobia.

         10. Patients with a contraindication to implantation of an implantable loop recorder (such
             as limited immunocompetence or a wound healing disorder).

         11. Patient has valvular atrial fibrillation [reference AHA guidelines].

         12. Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation.

         13. Patient had a severe, disabling stroke within one year prior to enrollment or any
             stroke within 14 days of enrollment.

         14. Patient with special risk factors for stroke unrelated to AF, specifically known
             thrombophilia/ hypercoagulability, uncontrolled hypertension (systolic blood pressure
             &gt;180 mmHg and/or diastolic blood pressure &gt;100 mmHg within 4 days of enrollment),
             untreated familial hyperlipidemia, known vascular anomaly (intracranial aneurysm/
             arteriovenous malformation or chronic vascular dissection), or known severe carotid
             disease.

         15. Pregnancy or breastfeeding.

         16. Women of childbearing age who refuse to use a highly effective and medically
             acceptable form of contraception throughout the study.

         17. Patients who are &gt; 85 years of age.

         18. Patients who are critically ill or who have a life expectancy &lt;3 years.

         19. Patients for whom the investigator believes that the trial is not in the interest of
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David H Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David H Birnie, MD</last_name>
    <phone>613-696-7269</phone>
    <email>dbirnie@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonya Jancar, RN,CRA,CCRP</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>19678</phone_ext>
    <email>ocean@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Centre</name>
      <address>
        <city>Norwood</city>
        <state>South Australia</state>
        <zip>5067</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prash Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Russell D Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Wyse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian/Fraser Clinical Trials</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J.P. LeMaitre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Deyell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Leather, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ratika Parkash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos Morillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benedict Glover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allan Skanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iqwal Mangat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugene Crystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital (UHN)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle Greiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Health Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Macle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitarie de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Champagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Francois Roux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chenyang Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <state>Bayern</state>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Johannes Brachmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Malte Kuniss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW Ruhr-Universitat Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Georg Nolker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-westfalen</state>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christoph Stellbrink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elektrophysiologie GFO-Kliniken Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-westfalen</state>
        <zip>53225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Schluter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Dinslaken</name>
      <address>
        <city>Dinslaken</city>
        <state>Nordrhein-westfalen</state>
        <zip>46535</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anja Dorszewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universitat Koln</name>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Steven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster Department fur Kardiologie und Angiologie</name>
      <address>
        <city>Munster</city>
        <state>Nordrhein-westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lars Eckardt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segeberger Liniken</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leon Iden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKSH Lubeck</name>
      <address>
        <city>Lubeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roland Tilz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentraliklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <state>Thuringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christoph Geller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Huemer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Abdul Parwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Willems</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerhard Hindricks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Centre</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eliyahu Kalfon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF ablation</keyword>
  <keyword>Anticoagulation AF ablation</keyword>
  <keyword>Stroke prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

